214 related articles for article (PubMed ID: 21426339)
1. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.
Puskas J; Skrombolas D; Sedlacek A; Lord E; Sullivan M; Frelinger J
Immunology; 2011 Jun; 133(2):206-20. PubMed ID: 21426339
[TBL] [Abstract][Full Text] [Related]
2. Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.
Skrombolas D; Sullivan M; Frelinger JG
J Interferon Cytokine Res; 2019 Apr; 39(4):233-245. PubMed ID: 30848689
[TBL] [Abstract][Full Text] [Related]
3. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
4. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
7. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Wei M; Marino J; Trowell A; Zhang H; Stromp Peraino J; Rajasekera PV; Madsen JC; Sachs DH; Huang CA; Benichou G; Wang Z
Protein Eng Des Sel; 2014 Sep; 27(9):289-95. PubMed ID: 25147093
[TBL] [Abstract][Full Text] [Related]
10. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Schanzer JM; Baeuerle PA; Dreier T; Kufer P
Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188
[TBL] [Abstract][Full Text] [Related]
11. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
12. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.
Rubinstein MP; Kovar M; Purton JF; Cho JH; Boyman O; Surh CD; Sprent J
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9166-71. PubMed ID: 16757567
[TBL] [Abstract][Full Text] [Related]
13. IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells.
Ward NC; Yu A; Moro A; Ban Y; Chen X; Hsiung S; Keegan J; Arbanas JM; Loubeau M; Thankappan A; Yamniuk AP; Davis JH; Struthers M; Malek TR
J Immunol; 2018 Nov; 201(9):2579-2592. PubMed ID: 30282751
[TBL] [Abstract][Full Text] [Related]
14. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.
Létourneau S; van Leeuwen EM; Krieg C; Martin C; Pantaleo G; Sprent J; Surh CD; Boyman O
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2171-6. PubMed ID: 20133862
[TBL] [Abstract][Full Text] [Related]
15. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
16. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.
Gillies SD; Lan Y; Wesolowski JS; Qian X; Reisfeld RA; Holden S; Super M; Lo KM
J Immunol; 1998 Jun; 160(12):6195-203. PubMed ID: 9637539
[TBL] [Abstract][Full Text] [Related]
17. Gelatinase B/matrix metalloproteinase-9 and other neutrophil proteases switch off interleukin-2 activity.
Rybakin V; Stas M; Ugarte-Berzal E; Noppen S; Vandooren J; Van Aelst I; Liekens S; Proost P; Opdenakker G
Biochem J; 2019 Aug; 476(15):2191-2208. PubMed ID: 31262730
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
[TBL] [Abstract][Full Text] [Related]
19. Construction of an anti-IL-1β scfv and TNFRI fusion protein and its therapeutic effect on RA mice model.
Kan F; Ren G; Guo M; Qi J; Zhang Y; Han Y; Zhang Y; Li D
Curr Pharm Biotechnol; 2014; 14(12):1048-61. PubMed ID: 24433504
[TBL] [Abstract][Full Text] [Related]
20. Directed evolution of super-secreted variants from phage-displayed human Interleukin-2.
Rojas G; Carmenate T; Santo-Tomás JF; Valiente PA; Becker M; Pérez-Riverón A; Tundidor Y; Ortiz Y; Fernandez de Cossio-Diaz J; Graça L; Dübel S; León K
Sci Rep; 2019 Jan; 9(1):800. PubMed ID: 30692603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
